Abstract
Hemostasis is the system of generation and destruction of thrombi. It consists of coagulation and thrombolysis and has a plasmatic part and a cellular one, the latter being the thrombocytes and endothelial cells for coagulation and the polymorphonuclear granulocytes (PMN) for thrombolysis. Main products of PMN are oxidants of the hypochlorite / chloramine-type that can generate the nonradical excited oxidant singlet molecular oxygen (1ΔO2 *). Physiologically, 1ΔO2 * reacts with methionine and cysteine residues and with carbenic structures in lipids, generating dioxetanes, which upon disruption emit photons in the blue spectrum of light (380-450 nm). It modifies some important hemostasis components in blood: 1ΔO2 * inactivates the factors I (fibrinogen), V, VIII, vWF, X, plasminogen activator inhibitor-1 (PAI-1), and 1ΔO2 * oxidation of plasminogen and fibrin facilitates their specific cleavage by plasminogen activators and plasmin. Furthermore, 1ΔO2 * downregulates thrombocyte-function and upregulates PMNfunction. Chloramines seem to be the main physiologic generators of 1ΔO2 * : in concentrations of 0.1-2 mM in blood they strongly inhibit coagulation and enhance thrombolysis. The biogenesis and reaction pattern of 1ΔO2 * is of importance to understand the PMN-physiology in hemostasis, giving rise to new therapy forms of thromboatherothrombosis in man.
Keywords: Singlet-Oxygen, hemostasis, thrombi, polymorphonuclear granulocytes, thrombolysis, nonradical excited oxidant, singlet molecular oxygen
Current Vascular Pharmacology
Title: Regulation of Hemostasis by Singlet-Oxygen (1ΔO2*)
Volume: 2 Issue: 4
Author(s): Thomas W. Stief
Affiliation:
Keywords: Singlet-Oxygen, hemostasis, thrombi, polymorphonuclear granulocytes, thrombolysis, nonradical excited oxidant, singlet molecular oxygen
Abstract: Hemostasis is the system of generation and destruction of thrombi. It consists of coagulation and thrombolysis and has a plasmatic part and a cellular one, the latter being the thrombocytes and endothelial cells for coagulation and the polymorphonuclear granulocytes (PMN) for thrombolysis. Main products of PMN are oxidants of the hypochlorite / chloramine-type that can generate the nonradical excited oxidant singlet molecular oxygen (1ΔO2 *). Physiologically, 1ΔO2 * reacts with methionine and cysteine residues and with carbenic structures in lipids, generating dioxetanes, which upon disruption emit photons in the blue spectrum of light (380-450 nm). It modifies some important hemostasis components in blood: 1ΔO2 * inactivates the factors I (fibrinogen), V, VIII, vWF, X, plasminogen activator inhibitor-1 (PAI-1), and 1ΔO2 * oxidation of plasminogen and fibrin facilitates their specific cleavage by plasminogen activators and plasmin. Furthermore, 1ΔO2 * downregulates thrombocyte-function and upregulates PMNfunction. Chloramines seem to be the main physiologic generators of 1ΔO2 * : in concentrations of 0.1-2 mM in blood they strongly inhibit coagulation and enhance thrombolysis. The biogenesis and reaction pattern of 1ΔO2 * is of importance to understand the PMN-physiology in hemostasis, giving rise to new therapy forms of thromboatherothrombosis in man.
Export Options
About this article
Cite this article as:
Stief W. Thomas, Regulation of Hemostasis by Singlet-Oxygen (1ΔO2*), Current Vascular Pharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570161043385420
DOI https://dx.doi.org/10.2174/1570161043385420 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ventilatory Support in Persistent Pulmonary Hypertension of the Newborn
Current Respiratory Medicine Reviews Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Minimally-Invasive and Non-Invasive Continuous Glucose Monitoring Systems: Indications, Advantages, Limitations and Clinical Aspects
Current Diabetes Reviews Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Thrombus Extraction Catheters vs. Angiojet Rheolytic Thrombectomy in Thrombotic Lesions/SV Grafts
Current Cardiology Reviews Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets Human Internal Jugular Valve M-mode Ultrasound Characterization
Current Neurovascular Research The Effect of Adult and Pediatric Cardiopulmonary Bypass on Pharmacokinetic and Pharmacodynamic Parameters
Current Clinical Pharmacology Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design Insights into Peptide Mediated Antibiofilm Treatment in Chronic Wound: A Bench to Bedside Approach
Current Protein & Peptide Science Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research Mechanical Circulatory Support of the Critically Ill Child Awaiting Heart Transplantation
Current Cardiology Reviews Editorial (Thematic Issue: Overview of Immunotherapy in Alzheimer’s Disease (AD) and Mechanisms of IVIG Neuroprotection in Preclinical Models of AD)
Current Alzheimer Research Recent Advances in Biomaterials for Tissue Engineering and Controlled Drug Delivery
Current Pharmaceutical Biotechnology Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry “Epileptic Encephalopathy” of Infancy and Childhood: Electro-Clinical Pictures and Recent Understandings
Current Neuropharmacology Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets Animal Models for Studying Neointima Formation
Current Vascular Pharmacology